Thomas Yunger, MD
Pulmonary Disease · Dayton, OHNPI 1962496844
Payments from drug & device makers
Across 1,105 payments — averaging $362.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$345K
- AstraZeneca$33K
- Boehringer Ingelheim$6K
- Sanofi US Services Inc.$6K
- Shire North American Group Inc$3K
- Grifols USA, LLC$1K
- plus $8K from 33 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 449 | $344,768 |
| AstraZeneca(2 entities) | 150 | $32,911 |
| Boehringer Ingelheim | 92 | $5,895 |
| Sanofi US Services Inc. | 1 | $5,500 |
| Shire North American Group Inc | 4 | $3,222 |
| Grifols USA, LLC | 60 | $1,102 |
| Regeneron Healthcare Solutions, Inc. | 35 | $891 |
| Sanofi | 36 | $873 |
| Genentech USA, Inc. | 50 | $819 |
| Actelion Pharmaceuticals US, Inc. | 48 | $677 |
| Viiv Healthcare Company | 1 | $600 |
| Inspire Medical Systems, Inc. | 13 | $555 |
| Merck | 28 | $415 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $377 |
| United Therapeutics Corporation | 17 | $337 |
| Axsome Therapeutics, Inc. | 17 | $305 |
| Jazz Pharmaceuticals Inc. | 12 | $205 |
| Amgen | 10 | $189 |
| Pulmonx Corporation | 6 | $185 |
| Insmed, Inc. | 7 | $138 |
| Mylan Specialty L.p. | 8 | $131 |
| Baxter Healthcare | 4 | $121 |
| Teva Pharmaceuticals USA, Inc. | 7 | $117 |
| Bayer | 6 | $106 |
| Lilly USA, LLC | 1 | $90 |
| Gilead | 4 | $71 |
| Novartis | 4 | $64 |
| Kaleo, Inc. | 3 | $47 |
| Verona Pharma, Inc. | 2 | $43 |
| Viatris Specialty LLC | 2 | $31 |
| Astellas Pharma US Inc | 1 | $23 |
| Shionogi Inc | 1 | $22 |
| Mallinckrodt Enterprises LLC | 1 | $21 |
| AbbVie | 1 | $15 |
| Philips North America LLC | 1 | $15 |
| Intercept Pharmaceuticals, Inc. | 1 | $14 |
| Chiesi USA, Inc. | 1 | $13 |
| Paratek Pharmaceuticals, Inc. | 1 | $13 |
| Johnson & Johnson | 1 | $12 |
How this compares
$400,934 in reported general payments places this provider in the 95th percentile of 571 pulmonary disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Dayton
- Daniel PearsonDayton$61K
- Bruce CorserCincinnati$8.2M
- Edward CordascoColumbus$8M
- Kristin HighlandCleveland$3.2M
- Brian ZenoColumbus$2.9M
- Jean ElwingCincinnati$2.4M
- Roy St JohnColumbus$1.9M
- Nishant GuptaCincinnati$1.5M
- Robert BaughmanCincinnati$1.1M
- Francis McCormackCincinnati$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.